FDA weighs peptide policy against enforcement on unlawful peptide sellers
A legal analysis describes the agency splitting its approach between compounding policy questions and actions against sellers marketing peptides outside approved channels.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 21 16:03 ETSource: JD Supra
The wire
- 01A JD Supra legal analysis describes the FDA balancing ongoing peptide compounding policy work with enforcement against sellers distributing peptides unlawfully.
- 02Compounding pharmacies, clinics and research-peptide vendors are the parties exposed to the enforcement side of that split.
- 03The item is attorney commentary rather than a new FDA announcement, and no specific warning letters or categories were detailed.
From the source
Read at jdsupra.comFDA Balances Peptide Policy with Enforcement Against Unlawful Peptide Sellers